Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

891 questions · 902 findings · 317 reviews

No studies found 210 · 23.3%GRADE not reported 56 · 6.2%Very low 236 · 26.2%Low 220 · 24.4%Moderate 146 · 16.2%High 34 · 3.8%

Leflunomide vs methotrexate

Serious adverse events* · adults with renal vasculitis for maintenance therapy

Leflunomide showed no clear difference in serious adverse events* compared with methotrexate (low certainty).

1 finding from 1 review

Intervention not reported

Adverse events (AEs) (grade 3 or 4) ‐ Network included 19 pairwise comparisons ‐ Mean risk with SUN across trials3 in this network: 70.6% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
1 finding from 1 review

Intervention not reported

Serious adverse events (SAEs) ‐ Network included 31 pairwise comparisons ‐ Mean risk with SUN across trials3 included in this network: 40.7% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).

1 finding from 1 review